Cargando…
Blood pressure lowering effects of β‐blockers as add‐on or combination therapy: A meta‐analysis of randomized controlled trials
The authors performed a meta‐analysis to assess the efficacy of non‐atenolol β‐blockers as add‐on to monotherapy or as a component of combination antihypertensive therapy in patients with hypertension. The authors searched and identified relevant randomized controlled trials from PubMed until Novemb...
Autores principales: | Guo, Qian‐Hui, Zhu, Zhi‐Ming, Feng, Ying‐Qing, Lin, Jin‐Xiu, Wang, Ji‐Guang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9994166/ https://www.ncbi.nlm.nih.gov/pubmed/36756690 http://dx.doi.org/10.1111/jch.14616 |
Ejemplares similares
-
Association of alpha-ADD1 Gene and Hypertension Risk: A Meta-Analysis
por: Liao, Xiaoyang, et al.
Publicado: (2015) -
Allicin as add-on therapy for Helicobacter pylori infection: A systematic review and meta-analysis
por: Si, Xiao-Bei, et al.
Publicado: (2019) -
Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease
por: Huang, Rong-Shuang, et al.
Publicado: (2016) -
Genome‐Wide Meta‐Analysis of Blood Pressure Response to β(1)‐Blockers: Results From ICAPS (International Consortium of Antihypertensive Pharmacogenomics Studies)
por: Singh, Sonal, et al.
Publicado: (2019) -
Is the newest angiotensin‐receptor blocker azilsartan medoxomil more efficacious in lowering blood pressure than the older ones? A systematic review and network meta‐analysis
por: Wang, Ji‐Guang, et al.
Publicado: (2021)